Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, postponed its IPO on Friday. It had filed to raise $40 million by offering 2.9 million shares at a price range of $13 to $15.
The Milford, MA-based company was founded in 2002. It had planned to list on the Nasdaq under the symbol SBPH. William Blair and Wedbush PacGrow were set to be the joint bookrunners on the deal.
